CytomX Therapeutics IncNASDAQ:CTMX
- LAST PRICE1.2900
- TODAY'S CHANGE (%)-0.0100 (-0.7692%)
- Bid / Lots1.2900/ 5
- Ask / Lots1.3300/ 1
- Open / Previous Close1.3000 / 1.3000
- Day Range
- 52 Week Range
- Volume517,634
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CTMX |
|---|---|---|
| 09:32 ET | 6857 | 1.3 |
| 09:34 ET | 100 | 1.29 |
| 09:36 ET | 800 | 1.28 |
| 09:38 ET | 2417 | 1.2741 |
| 09:39 ET | 4600 | 1.27 |
| 09:41 ET | 300 | 1.275 |
| 09:43 ET | 800 | 1.27 |
| 09:45 ET | 3400 | 1.2701 |
| 09:48 ET | 2300 | 1.275 |
| 09:50 ET | 2558 | 1.275 |
| 09:52 ET | 2505 | 1.2711 |
| 09:54 ET | 2183 | 1.275 |
| 09:56 ET | 1598 | 1.275 |
| 09:57 ET | 2201 | 1.2711 |
| 09:59 ET | 1298 | 1.27 |
| 10:01 ET | 600 | 1.275 |
| 10:03 ET | 300 | 1.27 |
| 10:06 ET | 1498 | 1.275 |
| 10:08 ET | 4437 | 1.285 |
| 10:10 ET | 1300 | 1.28 |
| 10:12 ET | 100 | 1.27 |
| 10:14 ET | 200 | 1.27 |
| 10:15 ET | 200 | 1.275 |
| 10:17 ET | 500 | 1.275 |
| 10:19 ET | 100 | 1.275 |
| 10:24 ET | 100 | 1.275 |
| 10:26 ET | 2760 | 1.28 |
| 10:28 ET | 1398 | 1.28 |
| 10:30 ET | 317 | 1.275 |
| 10:32 ET | 700 | 1.28 |
| 10:33 ET | 1830 | 1.2712 |
| 10:35 ET | 3425 | 1.285 |
| 10:37 ET | 400 | 1.285 |
| 10:39 ET | 1200 | 1.28 |
| 10:42 ET | 400 | 1.285 |
| 10:44 ET | 400 | 1.29 |
| 10:46 ET | 200 | 1.29 |
| 10:48 ET | 500 | 1.29 |
| 10:50 ET | 400 | 1.285 |
| 10:51 ET | 19647 | 1.29 |
| 10:53 ET | 5318 | 1.28 |
| 10:55 ET | 2170 | 1.29 |
| 10:57 ET | 300 | 1.29 |
| 11:00 ET | 400 | 1.29 |
| 11:02 ET | 200 | 1.285 |
| 11:04 ET | 200 | 1.285 |
| 11:06 ET | 200 | 1.285 |
| 11:08 ET | 500 | 1.2864 |
| 11:09 ET | 1100 | 1.28 |
| 11:11 ET | 200 | 1.285 |
| 11:13 ET | 1300 | 1.285 |
| 11:15 ET | 200 | 1.285 |
| 11:18 ET | 300 | 1.28 |
| 11:20 ET | 200 | 1.285 |
| 11:22 ET | 100 | 1.28 |
| 11:26 ET | 400 | 1.28 |
| 11:27 ET | 500 | 1.2801 |
| 11:29 ET | 100 | 1.285 |
| 11:31 ET | 100 | 1.28 |
| 11:33 ET | 200 | 1.285 |
| 11:36 ET | 100 | 1.28 |
| 11:38 ET | 400 | 1.28 |
| 11:40 ET | 600 | 1.28 |
| 11:44 ET | 200 | 1.285 |
| 11:45 ET | 300 | 1.285 |
| 11:47 ET | 100 | 1.285 |
| 11:49 ET | 4662 | 1.29 |
| 11:51 ET | 6255 | 1.3 |
| 11:54 ET | 13546 | 1.29 |
| 11:56 ET | 1611 | 1.3 |
| 11:58 ET | 300 | 1.295 |
| 12:00 ET | 600 | 1.29 |
| 12:02 ET | 1400 | 1.295 |
| 12:03 ET | 300 | 1.29 |
| 12:05 ET | 300 | 1.29 |
| 12:07 ET | 300 | 1.29 |
| 12:09 ET | 1907 | 1.29 |
| 12:12 ET | 500 | 1.29 |
| 12:14 ET | 6169 | 1.28 |
| 12:16 ET | 500 | 1.28 |
| 12:18 ET | 600 | 1.28 |
| 12:20 ET | 400 | 1.285 |
| 12:21 ET | 400 | 1.28 |
| 12:23 ET | 400 | 1.28 |
| 12:25 ET | 200 | 1.28 |
| 12:27 ET | 500 | 1.28 |
| 12:30 ET | 200 | 1.28 |
| 12:32 ET | 1489 | 1.285 |
| 12:34 ET | 7644 | 1.28 |
| 12:36 ET | 600 | 1.27 |
| 12:38 ET | 600 | 1.275 |
| 12:39 ET | 200 | 1.27 |
| 12:41 ET | 4685 | 1.275 |
| 12:43 ET | 500 | 1.275 |
| 12:45 ET | 1000 | 1.27 |
| 12:48 ET | 3630 | 1.28 |
| 12:50 ET | 500 | 1.27 |
| 12:52 ET | 500 | 1.275 |
| 12:54 ET | 3227 | 1.28 |
| 12:56 ET | 600 | 1.27 |
| 12:57 ET | 2743 | 1.275 |
| 12:59 ET | 200 | 1.275 |
| 01:01 ET | 500 | 1.27 |
| 01:03 ET | 3161 | 1.275 |
| 01:06 ET | 300 | 1.275 |
| 01:08 ET | 500 | 1.27 |
| 01:10 ET | 3949 | 1.27 |
| 01:12 ET | 500 | 1.27 |
| 01:14 ET | 194 | 1.27 |
| 01:15 ET | 2642 | 1.28 |
| 01:17 ET | 800 | 1.27 |
| 01:19 ET | 500 | 1.27 |
| 01:21 ET | 400 | 1.27 |
| 01:24 ET | 2512 | 1.28 |
| 01:26 ET | 500 | 1.275 |
| 01:28 ET | 300 | 1.27 |
| 01:30 ET | 400 | 1.28 |
| 01:32 ET | 2921 | 1.275 |
| 01:33 ET | 400 | 1.27 |
| 01:35 ET | 300 | 1.27 |
| 01:37 ET | 400 | 1.27 |
| 01:39 ET | 2837 | 1.27 |
| 01:42 ET | 2500 | 1.27 |
| 01:44 ET | 200 | 1.27 |
| 01:46 ET | 300 | 1.27 |
| 01:48 ET | 2935 | 1.275 |
| 01:50 ET | 500 | 1.27 |
| 01:51 ET | 1469 | 1.27 |
| 01:53 ET | 5179 | 1.28 |
| 01:55 ET | 300 | 1.275 |
| 01:57 ET | 900 | 1.28 |
| 02:00 ET | 900 | 1.27 |
| 02:02 ET | 2636 | 1.28 |
| 02:04 ET | 600 | 1.27 |
| 02:06 ET | 6920 | 1.28 |
| 02:08 ET | 900 | 1.27 |
| 02:09 ET | 400 | 1.275 |
| 02:11 ET | 600 | 1.27 |
| 02:13 ET | 400 | 1.27 |
| 02:15 ET | 2679 | 1.28 |
| 02:18 ET | 400 | 1.275 |
| 02:20 ET | 300 | 1.275 |
| 02:22 ET | 900 | 1.275 |
| 02:24 ET | 682 | 1.275 |
| 02:26 ET | 3538 | 1.275 |
| 02:27 ET | 400 | 1.27 |
| 02:29 ET | 600 | 1.275 |
| 02:31 ET | 2578 | 1.27 |
| 02:33 ET | 1678 | 1.275 |
| 02:36 ET | 500 | 1.27 |
| 02:38 ET | 700 | 1.27 |
| 02:40 ET | 2643 | 1.27 |
| 02:42 ET | 500 | 1.27 |
| 02:44 ET | 400 | 1.27 |
| 02:45 ET | 11818 | 1.275 |
| 02:47 ET | 541 | 1.275 |
| 02:49 ET | 300 | 1.27 |
| 02:51 ET | 558 | 1.275 |
| 02:54 ET | 3936 | 1.27 |
| 02:56 ET | 742 | 1.27 |
| 02:58 ET | 400 | 1.27 |
| 03:00 ET | 900 | 1.275 |
| 03:02 ET | 3138 | 1.275 |
| 03:03 ET | 700 | 1.275 |
| 03:05 ET | 1000 | 1.27 |
| 03:07 ET | 1300 | 1.275 |
| 03:09 ET | 5509 | 1.275 |
| 03:12 ET | 1500 | 1.28 |
| 03:14 ET | 400 | 1.28 |
| 03:16 ET | 2619 | 1.28 |
| 03:18 ET | 2566 | 1.275 |
| 03:20 ET | 1200 | 1.27 |
| 03:21 ET | 21353 | 1.29 |
| 03:23 ET | 2602 | 1.28 |
| 03:25 ET | 700 | 1.285 |
| 03:27 ET | 1600 | 1.285 |
| 03:30 ET | 3748 | 1.285 |
| 03:32 ET | 2618 | 1.28 |
| 03:34 ET | 2639 | 1.28 |
| 03:36 ET | 2941 | 1.285 |
| 03:38 ET | 7559 | 1.28 |
| 03:39 ET | 715 | 1.285 |
| 03:41 ET | 4514 | 1.28 |
| 03:43 ET | 792 | 1.28 |
| 03:45 ET | 9508 | 1.3 |
| 03:48 ET | 1800 | 1.29 |
| 03:50 ET | 500 | 1.295 |
| 03:52 ET | 4164 | 1.295 |
| 03:54 ET | 800 | 1.295 |
| 03:56 ET | 1540 | 1.29 |
| 03:57 ET | 4546 | 1.29 |
| 03:59 ET | 145797 | 1.29 |
Jun 18, 2024
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 17, 2024
DJ CytomX Therapeutics Promotes Chris Ogden to CFO, from 5:12PM ET on Monday Jun 17, 2024 by Dow Jones
5:12PM ET on Monday Jun 17, 2024 by Dow JonesPress Release: CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer, from 4:15PM ET on Monday Jun 17, 2024 by Dow Jones
4:15PM ET on Monday Jun 17, 2024 by Dow JonesCytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer, from 4:15PM ET on Monday Jun 17, 2024 by Dow Jones
4:15PM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CytomX Therapeutics Inc | 101.3M | 6.5x | --- |
Spero Therapeutics Inc | 71.5M | 3.1x | --- |
2Seventy Bio Inc | 206.1M | -0.9x | --- |
Rigel Pharmaceuticals Inc | 135.7M | -6.9x | --- |
G1 Therapeutics Inc | 134.4M | -4.1x | --- |
Seres Therapeutics Inc | 106.3M | -1.3x | --- |
Company Information
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Contact Information
- Headquarters
- 151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-515-3185
- Fax
- 650-351-0353
Executives
- Chairman of the Board, Chief Executive Officer
- Sean Mccarthy
- Chief Financial Officer
- Chris Ogden
- Senior Vice President, Chief Scientific Officer
- Marcia Belvin
- Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
- Lloyd Rowland
- Senior Vice President, Chief Business Officer and Head of Strategy
- Jeffrey Landau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $101.3M |
|---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 6.5x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 5.5x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
